Moreover, the 36-month beta value for PACB is 1.94. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for PACB is 241.81M and currently, short sellers hold a 23.51% of that float. On January 13, 2025, PACB’s average trading volume was 9.82M shares.
PACB) stock’s latest price update
Pacific Biosciences of California Inc (NASDAQ: PACB) has experienced a decline in its stock price by 0.00 compared to its previous closing price of 2.10. However, the company has seen a gain of 16.67% in its stock price over the last five trading days. zacks.com reported 2025-01-10 that PacBio delivers the first Vega systems to Berry Genomics to develop and optimize its targeted assays to support screening programs in China and other markets.
PACB’s Market Performance
Pacific Biosciences of California Inc (PACB) has experienced a 16.67% rise in stock performance for the past week, with a -3.67% drop in the past month, and a 30.43% rise in the past quarter. The volatility ratio for the week is 10.50%, and the volatility levels for the past 30 days are at 9.25% for PACB. The simple moving average for the past 20 days is 6.83% for PACB’s stock, with a 10.47% simple moving average for the past 200 days.
Analysts’ Opinion of PACB
Jefferies, on the other hand, stated in their research note that they expect to see PACB reach a price target of $4. The rating they have provided for PACB stocks is “Buy” according to the report published on June 03rd, 2024.
PACB Trading at 4.02% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.24% of loss for the given period.
Volatility was left at 9.25%, however, over the last 30 days, the volatility rate increased by 10.50%, as shares sank -10.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.13% upper at present.
During the last 5 trading sessions, PACB rose by +16.67%, which changed the moving average for the period of 200-days by -41.83% in comparison to the 20-day moving average, which settled at $1.97. In addition, Pacific Biosciences of California Inc saw 14.75% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PACB starting from Van Oene Mark, who sale 34,405 shares at the price of $2.03 back on Jan 10 ’25. After this action, Van Oene Mark now owns 1,597,454 shares of Pacific Biosciences of California Inc, valued at $69,980 using the latest closing price.
MARK VAN OENE, the Officer of Pacific Biosciences of California Inc, proposed sale 34,405 shares at $2.03 during a trade that took place back on Jan 10 ’25, which means that MARK VAN OENE is holding shares at $69,980 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -2.15 for the present operating margin
- 0.18 for the gross margin
The net margin for Pacific Biosciences of California Inc stands at -2.28. The total capital return value is set at -0.27. Equity return is now at value -64.80, with -23.55 for asset returns.
Based on Pacific Biosciences of California Inc (PACB), the company’s capital structure generated 0.66 points at debt to capital in total, while cash flow to debt ratio is standing at -0.26. The debt to equity ratio resting at 1.97. The interest coverage ratio of the stock is -26.21.
Currently, EBITDA for the company is -277.28 million with net debt to EBITDA at -2.63. When we switch over and look at the enterprise to sales, we see a ratio of 8.19. The receivables turnover for the company is 5.89for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.74.
Conclusion
To wrap up, the performance of Pacific Biosciences of California Inc (PACB) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
